JP2018111728A5 - - Google Patents

Download PDF

Info

Publication number
JP2018111728A5
JP2018111728A5 JP2018080510A JP2018080510A JP2018111728A5 JP 2018111728 A5 JP2018111728 A5 JP 2018111728A5 JP 2018080510 A JP2018080510 A JP 2018080510A JP 2018080510 A JP2018080510 A JP 2018080510A JP 2018111728 A5 JP2018111728 A5 JP 2018111728A5
Authority
JP
Japan
Prior art keywords
human
composition
eculizumab
administered
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018080510A
Other languages
English (en)
Japanese (ja)
Other versions
JP6505288B2 (ja
JP2018111728A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018111728A publication Critical patent/JP2018111728A/ja
Publication of JP2018111728A5 publication Critical patent/JP2018111728A5/ja
Application granted granted Critical
Publication of JP6505288B2 publication Critical patent/JP6505288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018080510A 2013-03-29 2018-04-19 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 Active JP6505288B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361806687P 2013-03-29 2013-03-29
US61/806,687 2013-03-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016505600A Division JP6505079B2 (ja) 2013-03-29 2014-03-28 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018111728A JP2018111728A (ja) 2018-07-19
JP2018111728A5 true JP2018111728A5 (OSRAM) 2018-12-27
JP6505288B2 JP6505288B2 (ja) 2019-04-24

Family

ID=50686201

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016505600A Active JP6505079B2 (ja) 2013-03-29 2014-03-28 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
JP2018080510A Active JP6505288B2 (ja) 2013-03-29 2018-04-19 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016505600A Active JP6505079B2 (ja) 2013-03-29 2014-03-28 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法

Country Status (6)

Country Link
US (3) US20160051673A1 (OSRAM)
EP (2) EP2978451B1 (OSRAM)
JP (2) JP6505079B2 (OSRAM)
CA (1) CA2897334A1 (OSRAM)
ES (1) ES2768648T3 (OSRAM)
WO (1) WO2014160958A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
WO2014160129A2 (en) 2013-03-14 2014-10-02 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
US20180142010A1 (en) * 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3328885A1 (en) * 2015-09-11 2018-06-06 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
LT3468990T (lt) 2016-06-14 2024-06-25 Regeneron Pharmaceuticals, Inc. Anti-c5 antikūnai ir jų panaudojimas
TWI807666B (zh) * 2016-06-17 2023-07-01 日商中外製藥股份有限公司 抗c5抗體及使用方法
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US11828683B2 (en) 2016-10-19 2023-11-28 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5a in a sample
ES2848206T3 (es) * 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
WO2018143266A1 (en) * 2017-01-31 2018-08-09 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
KR102656199B1 (ko) * 2017-04-21 2024-04-09 볼루션 이뮤노 파마슈티컬스 에스에이 자가면역 수포 질환의 치료를 위한 코버신
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
EP3597222A1 (en) * 2018-07-16 2020-01-22 Easemedcontrol R & D GmbH & Co KG Treatment and diagnosis of unresolved inflammatory diseases
MX2021002710A (es) * 2018-09-06 2021-09-23 Univ Pennsylvania Anticuerpos anti-c5 humanizados y usos de los mismos.
SG11202111419QA (en) * 2019-04-24 2021-11-29 Univ Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
WO2021154941A1 (en) * 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
US20240417725A1 (en) * 2021-10-12 2024-12-19 Vanqua Bio, Inc. Oligonucleotides for targeting complement c5

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
BRPI0212496B8 (pt) 2001-09-12 2021-06-22 Becton Dickinson And Company Bd dispositivo tipo caneta baseado em uma micro agulha para distribuição de medicamentos e método de utilização do mesmo
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
JP4339852B2 (ja) 2002-08-12 2009-10-07 ニュー・イングランド・バイオラブズ・インコーポレイティッド 遺伝子サイレンシングに関する方法および組成物
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
ES2674129T3 (es) 2004-02-12 2018-06-27 Archemix Llc Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2007223796B2 (en) 2006-03-08 2013-01-24 Astellas Us Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BRPI0916668B1 (pt) 2008-08-05 2021-12-28 Novartis Ag Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
AU2011223866B2 (en) * 2010-03-01 2015-05-21 Alexion Pharmaceuticals Inc. Methods and compositions for treating Degos' disease
WO2014160129A2 (en) 2013-03-14 2014-10-02 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2018111728A5 (OSRAM)
JP2018193377A5 (OSRAM)
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
JP2017149726A5 (OSRAM)
PH12022551169A1 (en) METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
JP2014111603A5 (OSRAM)
JP2016540785A5 (OSRAM)
JP2016503398A5 (OSRAM)
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
JP2012506448A5 (OSRAM)
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
JP2006504795A5 (OSRAM)
JP2013231087A5 (OSRAM)
JP2017502074A5 (OSRAM)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2018509388A5 (OSRAM)
JP2018529666A5 (OSRAM)
RU2016114098A (ru) Новое производное аналога инсулина
HRP20230070T1 (hr) Tasimelteon za liječenje smith-magenis sindroma
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
JP2022062153A5 (OSRAM)
JP2013520448A5 (OSRAM)
JP2019515033A5 (OSRAM)
JP2016537364A5 (OSRAM)